List view / Grid view
The new acquisition, worth up to $2.1 billion, gives AbbVie…
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
The FDA’s authorisation helps to address the “significant” remaining need…
The FDA’s authorisation helps to address the “significant” remaining need for acute hepatitis C treatments, according to AbbVie.
The deal will help AbbVie to strengthen its neuroscience pipeline,…
The deal will help AbbVie to strengthen its neuroscience pipeline, including supporting development of next-generation therapies for delivery into the central nervous system.
Following the appointment, Thomas Hudson, AbbVie’s current Senior Vice President,…
Following the appointment, Thomas Hudson, AbbVie’s current Senior Vice President, Chief Scientific Officer, Global Research, will retire.
